AIDSinfo Launches User-Friendly Clinical Trials Search
Recognizing that people need a quick way to find information about HIV/AIDS-related clinical trials, AIDSinfo has redesigned its Web pages that link to ClinicalTrials.gov. Visitors to AIDSinfo and infoSIDA now have two-click access to more than 80 formatted searches for HIV/AIDS-related trials in 10 different categories.
The redesign of the clinical trial search pages on AIDSinfo and infoSIDA was done in direct response to feedback from Web site users. A 2011 usability study revealed a clear need for improvements to the previous navigation, including prominent placement of preconfigured searches.
As an example, to access information on more than 100 studies of preventive vaccines for HIV/AIDS from the ClinicalTrials.gov database, visitors to AIDSinfo and infoSIDA need only click “Vaccine Research” on the clinical trials page and then “HIV Preventive Vaccines.” A pull-down menu on the resulting page allows users to further narrow the list to either “Studies Seeking New Volunteers” or “Studies with Results.” Other categories represented on the clinical trials page include cancer, coinfections, complications/side effects, opportunistic infections, prevention research, specific populations, treatment research, trials by age, and trials by study type.
In creating the formatted searches, AIDSinfo staff focused on ensuring that the results would deliver targeted yet complete and up-to-date information on the HIV/AIDS clinical trials represented in ClinicalTrials.gov. Research results obtained through the AIDSinfo landing page are in English, whereas the infoSIDA page returns results in Spanish.
Should you need help with your search for clinical trials in HIV/AIDS, AIDSinfo health information specialists are available via our Internet Live Chat service or by phone (800-448-0440).
We would also like to hear from you! AIDSinfo is committed to continually making improvements. You can submit feedback by calling us at 800-448-0440, e-mailing us at email@example.com, or chatting with us.
Study Examines Timing of Treatment Initiation and Clinical Outcomes in HIV-Infected People
“[The purpose of the study is to] estimate the clinical benefit of highly active antiretroviral therapy (HAART) initiation vs deferral in a given month in patients with CD4 cell counts less than 800/μL. …
“In this observational cohort study of human immunodeficiency virus type 1 seroconverters from CASCADE (Concerted Action on SeroConversion to AIDS and Death in Europe), we constructed monthly sequential nested subcohorts between January 1996 and May 2009, including all eligible HAART-naive, AIDS-free individuals with a CD4 cell count less than 800/μL. The primary outcome was time to AIDS or death in those who initiated HAART in the baseline month compared with those who did not, pooled across subcohorts and stratified by CD4 cell count. …
“Of 9455 patients with 52 268 person-years of follow-up, 812 (8.6%) developed AIDS and 544 (5.8%) died. In CD4 cell count strata of 200 to 349, 350 to 499, and 500 to 799/μL, HAART initiation was associated with adjusted hazard ratios (95% CIs) for AIDS/death of 0.59 (0.43-0.81), 0.75 (0.49-1.14), and 1.10 (0.67-1.79), respectively. In the analysis of all-cause mortality, HAART initiation was associated with adjusted hazard ratios (95% CIs) of 0.71 (0.44-1.15), 0.51 (0.33-0.80), and 1.02 (0.49-2.12), respectively. Numbers needed to treat (95% CIs) to prevent 1 AIDS event or death within 3 years were 21 (14-38) and 34 (20-115) in CD4 cell count strata of 200 to 349 and 350 to 499/μL, respectively. …
“Compared with deferring in a given month, HAART initiation at CD4 cell counts less than 500/μL (but not 500-799/μL) was associated with slower disease progression.”
More information is available: